PURPOSE: To report a single biomarker, psoriasin (Mr 11.0 kd, pI 6.2), a calcium binding protein which is expressed largely by stratified squamous epithelia and is externalized to the urine of bladder squamous cell carcinoma (SCC) bearing patients. MATERIALS AND METHODS: Protein expression profiles of SCCs obtained immediately after surgery were analyzed by two-dimensional gel electrophoresis and Coomassie blue staining. Protein identity was determined by microsequencing and immunoblotting. Protein expression in cryosections was studied by immunofluorescence. RESULTS: Four patients with SCC were identified from 100 samples of patients with suspected transitional cell carcinoma (TCC). The protein profiles of the 4 SCCs (56-1, grade III, T4; 181-1, grade I, T3; 219-1, grade III, T3 and 239-1, grade not determined, T2-4) resembled that of keratinocytes, suggesting that these cells express an early developmental pattern of gene expression. Besides expressing markers characteristic of keratinizing stratified squamous epithelia, the SCCs exhibited psoriasin, a protein externalized to the medium by keratinocytes. Immunohistochemistry of 3 of the SCCs with psoriasin antibodies showed that the positive cells were confined chiefly to the "squamous pearls." The presence of psoriasin in the urine of the 4 SCC patients was demonstrated by two-dimensional gel immunoblotting. Similar analysis of 43 urines from patients with bladder tumors other than SCC revealed 7 positives, some of which may reflect squamous differentiation. Analysis of the urine of 13 control individuals (12 males matched by age and a 42-year-old female) revealed 2 positives. Immunoblotting of the SCC patients' serum proteins with psoriasin antibodies failed to reveal the protein. CONCLUSION: The results point towards psoriasin, alone or as part of a biomarker profile, as a potential marker for the noninvasive follow-up of patients with SCC.
PURPOSE: To report a single biomarker, psoriasin (Mr 11.0 kd, pI 6.2), a calcium binding protein which is expressed largely by stratified squamous epithelia and is externalized to the urine of bladder squamous cell carcinoma (SCC) bearing patients. MATERIALS AND METHODS: Protein expression profiles of SCCs obtained immediately after surgery were analyzed by two-dimensional gel electrophoresis and Coomassie blue staining. Protein identity was determined by microsequencing and immunoblotting. Protein expression in cryosections was studied by immunofluorescence. RESULTS: Four patients with SCC were identified from 100 samples of patients with suspected transitional cell carcinoma (TCC). The protein profiles of the 4 SCCs (56-1, grade III, T4; 181-1, grade I, T3; 219-1, grade III, T3 and 239-1, grade not determined, T2-4) resembled that of keratinocytes, suggesting that these cells express an early developmental pattern of gene expression. Besides expressing markers characteristic of keratinizing stratified squamous epithelia, the SCCs exhibited psoriasin, a protein externalized to the medium by keratinocytes. Immunohistochemistry of 3 of the SCCs with psoriasin antibodies showed that the positive cells were confined chiefly to the "squamous pearls." The presence of psoriasin in the urine of the 4 SCC patients was demonstrated by two-dimensional gel immunoblotting. Similar analysis of 43 urines from patients with bladder tumors other than SCC revealed 7 positives, some of which may reflect squamous differentiation. Analysis of the urine of 13 control individuals (12 males matched by age and a 42-year-old female) revealed 2 positives. Immunoblotting of the SCC patients' serum proteins with psoriasin antibodies failed to reveal the protein. CONCLUSION: The results point towards psoriasin, alone or as part of a biomarker profile, as a potential marker for the noninvasive follow-up of patients with SCC.
Authors: S Al-Haddad; Z Zhang; E Leygue; L Snell; A Huang; Y Niu; T Hiller-Hitchcock; K Hole; L C Murphy; P H Watson Journal: Am J Pathol Date: 1999-12 Impact factor: 4.307
Authors: Jennifer K Plichta; Casey J Holmes; Vanessa Nienhouse; Michelle Puszynski; Xiang Gao; Qunfeng Dong; Huaiying Lin; James Sinacore; Michael Zilliox; Evelyn Toh; David E Nelson; Richard L Gamelli; Katherine A Radek Journal: Crit Care Med Date: 2017-06 Impact factor: 7.598
Authors: Noemi Moubayed; Michael Weichenthal; Jürgen Harder; Elke Wandel; Michael Sticherling; Regine Gläser Journal: J Cancer Res Clin Oncol Date: 2006-11-29 Impact factor: 4.553
Authors: Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey Journal: Cancer Cell Date: 2014-02-10 Impact factor: 31.743
Authors: James A DeVoti; David W Rosenthal; Rong Wu; Allan L Abramson; Bettie M Steinberg; Vincent R Bonagura Journal: Mol Med Date: 2008 Sep-Oct Impact factor: 6.354